updat baxter model review model
lower ep believ street estim may high though
believ buy-sid commun may alreadi think equal weight maintain
expect last week baxter file late file notic compani
continu investig intra-compani transact undertaken
purpos gener foreign exchang gain loss disclos along
preliminari result last month baxter also disclos still wait fda
inspect legaci clari facil warn letter meantim
work secur contract manufactur upcom new drug lower margin
accounting/fraud investig diminish credit/success
manag team receiv oper margin cash flow
improv baxter far stronger better-run compani today seem
investig isol transact non-oper incom said
still consid signific matter speak intern controls/oversight
compani last week manag still said there timelin updat
consensu ep may high though seem investor may alreadi
suspect reduc ep estim
maintain pt adjust target pe
call manag note review annual plan consid sever
factor propos kidney health initi capit invest
oper improv enhanc manufactur qualiti capabl
final gpo idn agreement think pension transfer could
headwind albeit non-oper share repurchas help ep growth last
year think account investig outstand limit share
repurchas sec file current baxter billion
avail share repurchas baxter deploy cash share repurchas
limit deploy strateg
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
expect reset lower
believ appropri level near-
term ep growth significantli aid financi
engin share repurchas believ
warrant lower valuat multipl rel other
sector think risk/reward fairli
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
accret
downsid case could driven greater-
pressur renal med deliveri fx rate
inabl drive pharma sale pharma price
inabl expand margin
sale came street/our estim result primarili driven
lower expect medic deliveri sale baxter announc intern probe
intra-compani transact use gener fx gains/loss incom due
investig baxter report anyth oper incom provid full
year guidanc updat baxter expect report sale growth constant
currenc oper growth oper margin net/net
view stock chang continu rate stock equal weight
million except per share data chang sale report basi baxter provid constant currenc result
addit detail quarter
oper margin estim y/i due
top line perform on-going oper effici
renal sale street expect driven
strength pd therapi patient volum increas y/i despit headwind
in-cent hd includ bloodlin busi exit impact revaclear
suppli constraint less impact
sale street report basi
baxter began intern investig intra-compani transact undertaken
order gener fx gains/loss report incom expens
line compani previous report net fx gain
year respect
medic deliveri sale street estim
manag still express confid ramp sale
clari facil re-inspect fda baxter work cmo
back-up think could risk new product outlook margin pharma
nutrit sale report basi street
estim
advanc surgeri sale roughli in-lin street
estim rel forecast baxter less benefit
 surgiflo suppli issu expect
sale constant currenc oper basi report growth
gross margin y/i benefit manufactur varianc
off-set dialyz suppli constraint issu reduc gross profit
sg sale y/i reflect disciplin focu manag
 sale y/i due benefit optim initi
oper margin y/i
given intern investig baxter provid result oper
incom line tax rate given
estim constant currenc result product
baxter expect sale growth report basi street expect top rang growth
constant currenc oper basi baxter also expect adjust oper margin
manag would comment state prepar remark consid capit invest support
advanc american kidney health initi invest make oper improv enhanc qualiti manufactur
capabl final agreement gpo idn hospit product busi
read note call click titl link barclay live
kstew note comment buy back comment beyond
access model click link
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
